| Cat # | Size | Price | Quantity | |
|---|---|---|---|---|
| 505501 | 1 mg | $175 | ||
| 505502 | 5 mg | $480 | ||
| 505503 | 20 mg | $960 | ||
| 505504 | 5 mg | $720 | ||
| 505505 | 20 mg | $1440 |
| Clone | Sacituzumab |
|---|---|
| Application | Flow cytometry, animal model study |
| Host Species | Mammalian cells |
| Format | Liquid |
| Product Description | Sacituzumab Biosimilar, Endotoxin 0.05 EU/mg |
| Isotype | Human IgG1 |
| Regulatory Status | RUO |
| Clonality | Recombinant |
| Immunogen | Human Trop-2 |
| Species specificity | Human |
| Purity | >95% by reducing SDS-PAGE |
| Grade | In vivo |
| Storage Conditions | 4ºC |
| Maximal Shelf Life | 12 months |
| See All Formats | Clone Sacituzumab |
Sacituzumab, as a therapeutic, is an antibody–drug conjugate (ADC) composed of a humanized monoclonal antibody targeted against trophoblast cell-surface antigen 2 (Trop-2) conjugated to a potent cytotoxic payload. Structurally, the antibody component belongs to the immunoglobulin G1 kappa (IgG1κ) subclass and has a molecular weight of approximately 150 kilodaltons (kDa). It consists of two identical heavy chains and two identical light chains linked by disulfide bridges, forming the characteristic Y-shaped configuration typical of immunoglobulins. The antibody is produced through recombinant DNA technology in mammalian expression systems, ensuring proper folding, glycosylation, and immunoglobulin stability.
The Trop-2-binding regions of Sacituzumab are located in the variable domains of its heavy (VH) and light (VL) chains, which contain complementarity-determining regions (CDRs) that confer high-affinity binding to a specific extracellular epitope on the Trop-2 glycoprotein. Trop-2 is a transmembrane calcium signal transducer involved in cellular proliferation and adhesion processes. The antibody’s recognition of Trop-2 leads to receptor-specific binding and internalization via endocytosis.
The Fc (fragment crystallizable) portion contributes to molecular stability and longevity through neonatal Fc receptor (FcRn) recycling.
Anti-Human TROP-2 (Sacituzumab Biosimilar) TDS
Have a product or application question? Consult our FAQs or contact us.
